Announcements
- G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
- G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
- G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
- G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
- G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
- G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
- G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
- G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
- G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
More ▼
Key statistics
On Friday, G1 Therapeutics Inc (G1H:STU) closed at 4.17, -7.58% below its 52-week high of 4.51, set on Feb 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.08 |
---|---|
High | 4.21 |
Low | 4.08 |
Bid | 4.11 |
Offer | 4.22 |
Previous close | 4.03 |
Average volume | 100.00 |
---|---|
Shares outstanding | 52.28m |
Free float | 46.19m |
P/E (TTM) | -- |
Market cap | 234.74m USD |
EPS (TTM) | -0.6146 USD |
Data delayed at least 15 minutes, as of May 03 2024.
More ▼